Evidence mapPaperPMID 42503192Full record

ArticleChemistry & biodiversity2026

Repurposing Camellia sinensis Roots and Ginkgo biloba Leaves for Multiple Myeloma via Wnt/β-Catenin-Dependent Cell Cycle Arrest and Apoptosis.

Mingge Li, Mingliang Zhang, Xubin Ma, Gaoquan Meng, Hui Zhang, Yingjie Ren, Linhong Fan, Yuhui Li, Yali Wu, Xiaoyan Wang and 3 more

Abstract read
In one paragraph

Article in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Mingge LiDepartment of Pharmacy, the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China.
Mingliang ZhangDepartment of Pharmacy, the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China.
Xubin MaDepartment of Pharmacy, the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China.
Gaoquan MengDepartment of Pharmacy, the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China.
Hui ZhangDepartment of Pharmacy, the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China.
Yingjie RenDepartment of Pharmacy, the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China.
Linhong FanDepartment of Pharmacy, the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China.
Yuhui LiDepartment of Pharmacy, the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China.
Yali WuDepartment of Pharmacy, the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China.
Xiaoyan WangDepartment of Pharmacy, the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China.ORCID https://orcid.org/0000-0002-3726-7687
Weixia LiDepartment of Pharmacy, the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China.
Xiaofei ChenDepartment of Pharmacy, the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China.
Jinfa TangDepartment of Pharmacy, the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China.

Funding

Doctoral Research Startup Fund of the First Affiliated Hospital of Henan University of Chinese Medicine KY-B0367-29High-quality Development of Traditional Chinese Medicine CXZH03Joint Construction Project of Henan Medical Science and Technology Research Plan SBGJ202403040Jointly-built Scientific Research Special Project of the National Traditional Chinese Medicine Inheritance and Innovation Center of Henan Provincial Health Commission 2024ZXZX1179Leading Talents in Science and Technology Entrepreneurship in Central Plains 254000510038National Natural Science Foundation of China 82004021National Natural Science Foundation of China 82173993National Natural Science Foundation of China U1904129Science and Technology Innovation Team in Universities of Henan Province 23IRTSTHN026
6 · The paper itself

Abstract

Multiple myeloma (MM) is a hematological malignancy with limited therapeutic options. Drug repurposing offers a pragmatic strategy to identify novel candidates, including those from Traditional Chinese Medicine (TCM). Here, a gene signature-guided repurposing approach was applied to transcriptomic data using Limma and weighted gene coexpression network analysis to define MM-associated hub genes, followed by diagnostic and prognostic evaluation. Coremine Medical screening identified Camellia sinensis root (CSR) and Ginkgo biloba leaves (GBL) as promising candidates. CSR and GBL extracts inhibited MM cell proliferation with IC

Indexed as

Antineoplastic Agents, PhytogenicApoptosisbeta CateninCell Cycle CheckpointsGinkgo bilobaMultiple MyelomaPlant ExtractsCell Line, TumorCell ProliferationDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansPlant LeavesPlant RootsWnt Signaling PathwayAntineoplastic Agents, Phytogenicbeta CateninPlant ExtractsCamellia sinensis rootdrug repurposingGinkgo biloba leavesmultiple myelomaβ‐catenin

Identifiers

PMID42503192
PMCPMC13401955

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.